Researchers at the NYU Pain Research Center have found a new receptor for nerve growth factor that plays an important role in ...

产品活性： Trastuzumab deruxtecan (T-DXd; DS-8201a) 是一种抗人表皮生长因子受体 2 (HER2) 抗体-活性分子偶联物 (ADC)。Trastuzumab deruxtecan 由人源化抗 HER2 ...

In an interview with Ophthalmology Times, Alon Kahana, MD, PhD, discusses interleukin-6 and its role in autoimmune diseases, particularly thyroid eye disease, noting that a promising alternative under ...

With more than 150 treatments being studied in clinical trials, what is on the horizon for antibody-drug conjugates in breast ...

Biotechnology, GlobeNewswire, Health, Product / Services Announcement | SPRING, Texas, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Io Therapeu ...

Seismic Therapeutic Inc. has provided preclinical data for S-4321, a novel dual-cell bidirectional (DcB) PD-1:FcγRIIb antibody being developed for the treatment of autoimmune disease.

Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...

Q32 Bio still sees potential for its anti-IL-7R antibody as an alopecia treatment despite failing a phase 2 eczema study—but ...

Merck (MRK) announced the first presentation of data from the Phase 2 waveLINE-007 trial evaluating zilovertamab vedotin, Merck’s ...

Incyte (INCY) announced results from the Phase 3 POD1UM-304 trial of retifanlimab, a humanized monoclonal antibody targeting programmed death ...

The anti-CX3CR1 antibody, currently in preclinical development, works by inhibiting CX3CR1, a receptor involved in immune cell migration to inflammatory sites. By accelerating its development, Asahi ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of data from ...